April 25th 2024
Despite the disproportionate effects of SARS-CoV-2 infection and severe outcomes on nursing home residents, less than 50% have received the updated 2023/2024 vaccine.
NIH Launches Trial Evaluating Second COVID-19 Booster Shots
March 31st 2022One day after the FDA approved second booster shots for certain vulnerable populations, the National Institute of Health (NIH) announced they have begun enrolling adult US participants in a phase 2 clinical trial to evaluate a second COVID-19 booster dose.
Read More
Pfizer-BioNTech and Moderna mRNA Vaccines Elicit Different Antibody Responses
March 30th 2022The Pfizer-BioNTech and Moderna mRNA vaccines were found to produce different antibody and killer T-cell responses, suggesting a “mix and match” booster approach may provide the best protection against COVID-19.
Read More
Booster Doses of mRNA Vaccines Protected Against Severe COVID-19 from Omicron
March 20th 2022Recent booster shots of mRNA vaccines prevented severe infection, hospitalization and death during the Omicron wave of the pandemic, despite a higher rate of breakthrough infections than was seen during the Delta wave, a new study found.
Read More
No Increased Risk of Neurological Conditions After COVID-19 Vaccination
March 17th 2022A study of over 8 million participants found no correlation between COVID-19 vaccination and developing neurological conditions. However, a risk of some neurological conditions was increased after COVID-19 infection.
Read More
Oral Nirmatrelvir Highly Effective Against COVID-19 in Phase 2/3 Trial
March 16th 2022Pfizer’s COVID-19 pill Paxlovid, which includes nirmatrelvir and ritonavir, reduced the risk of hospitalization and death by 89% among adults at high risk for severe disease, recently published phase 2/3 trial data show.
Read More
With New Variants, COVID-19 Vaccination Mildly Effective in Children
March 15th 2022In children and adolescents, the Pfizer-BioNTech vaccine was only mildly effective against symptomatic and asymptomatic COVID-19 infections. Broken down by variant, Omicron infections were more likely to occur and more likely to be asymptomatic.
Read More
Addressing COVID-19 Vaccine Efficacy Challenges in Younger Children
March 4th 2022This week, one of the m-RNA COVID-19 vaccine’s effectiveness was shown to drop from 68% to 12% in children 5-11 years old within a month. This data raises concerns of what should be done to protect this pediatric population.
Watch